Endocrinology Search
Endocrinology Endocrinology
growth%20hormone%20deficiency
GROWTH HORMONE DEFICIENCY
Growth hormone deficiency in adults reflects an absence of two hormones, growth hormone and insulin-like growth factor-1 (IGF-1), affecting the process of glucose-insulin metabolism, lipolysis and bone remodelling.
History may show pituitary adenoma, surgery &/or radiation treatment of pituitary adenomas or cranial radiation for other disorders, deficiency of other pituitary hormones that may occur concurrently with growth hormone deficiency, and previous childhood growth hormone deficiency.
Physical exam reveals reduced lean body mass with increased weight, body fat predominantly in the abdominal region, thin & dry skin, cool peripheries, poor venous access and blunt affect.

Growth Hormone Deficiency References

  1. Ayuk J, Sheppard MC. Growth hormone and its disorders. Postgrad Med J. 2006 Jan;82(963):24-30. PMID: 16397076
  2. Gharib H, Cook DM, Saenger PH, et al; American Association of Clinical Endocrinologists Growth Hormone Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children - 2003 update. Endocr Pract. 2003 Jan;9(1):64-76. doi: 10.4158/EP.9.1.64. PMID: 12917095
  3. Cook DM, Yuen KC, Biller BM, et al; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. Endocr Pract. 2009 Sep;15(Suppl 2):001-29. PMID: 20228036
  4. Berg C, Meinel T, Lahner H, et al. Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery. Eur J Endocrinol. 2010 Mar;162(3):477-482. PMID: 19996199
  5. Molitch ME, Clemmons DR, Malozowski S, et al; Endocrine Society's Clinical Guidelines Subcommittee. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2006 May;91(5):1621-1634. PMID: 16636129
  6. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab. 2000 Nov;85(11):3990-3993. http://dx.doi.org/10.1210/jcem.85.11.6984. PMID: 11095419
  7. Stavrou S, Kleinberg DL. Diagnosis and management of growth hormone deficiency in adults. Endocrinol Metab Clin North Am. 2001 Sep;30(3):545-563. PMID: 11571930
  8. Vance ML, Mauras N. Growth hormone therapy in adults & children. N Engl J Med. 1999 Oct;341(16):1206-1216. PMID: 10519899
  9. Saenger P. Growth hormone in growth hormone deficiency: start treatment early and give it for long enough. Br Med J. 2002 Jul;325(7355):58-59. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1123623/pdf/58.pdf. PMID: 12114222
  10. Yuen KC. Glucagon testing in adult growth hormone deficiency - current status and future perspectives. European Endocrinology. 2011;7(2):104-107
  11. Wilson TA, Rose SR, Cohen P, et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatrics. 2003 Oct;143(4):415-421. http://www.jpeds.com/article/S0022-3476(03)00246-4/pdf. PMID: 14571209
  12. Growth hormone replacement in adults with growth hormone deficiency. Harrison's Online: McGraw-Hill Companies; 2003. http://harrisonsonline.com
  13. Parks SP, Felner EI. Hypopituitarism. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson textbook of Pediatrics. 9th ed. Philadelphia, PA: Saunders, Elsevier; 2007.
  14. MedWormhttp://www.medworm.com/rss/index.php/Endocrinology/15/http://www.medworm.com/rss/medicalfeeds/specialities/Endocrinology.xml
  15. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  16. Growth hormone deficiency. Children’s hospital of Wisconsin. http://www.chw.org/display/PPF/DocID/22653/router.asp
  17. Kemp S. Pediatric Growth Hormone Deficiency. http://emedicine.medscape.com/article/923688-overview. Sep 2008
  18. Eledrisi MS. Growth hormone deficiency. eMedicine. http://emedicine.medscape.com/article/120767-overview. Jun 2008
  19. Kemp S. Growth hormone deficiency in children. eMedicine. http://www.emedicinehealth.comgrowth_hormone_deficiency_in_children/article_ em.htm. 2005
  20. Backeljauw PF, Dattani MT, Cohen P, Rosenfeld RG. Disorders of growth hormone/insulin-like growth factor secretion and action. In: Perling MA. Pediatric Endocrinology. 4th ed. Philadelphia, PA: Saunders, Elsevier Inc; 2014.
  21. Ho, KKY. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. European Journal of Endocrinology. 2007;157:695-700. doi: 10.1530/EJE-07-063.
  22. Molitch ME, Clemmons DR, Malozowski S, et al for The Endocrine Society’s Clinical Guidelines Subcommittee. Clinical practice guideline. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609. https://www.endocrine.org/~/media/endosociety/Files/Publications/Clinical%20Practice%20Guidelines/Evaluation-treatment-of-Adult-Growth-Hormone-Deficiency-Clinical-Practice-Guideline-NonCME.pdf. PMID: 21602453
  23. Wood AJ. Growth hormone therapy in adults & children. N Engl J Med. 1999;341(16):1206-1216.
  24. Ministry of Health Malaysia. The use of growth hormone in children and adults. MOH. http://www.acadmed.org.my/. Nov 2010.
  25. Allen DB, Backeljauw P, Bidlingmaier M, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016 Feb;174(2):P1-P9. http://www.eje-online.org/content/174/2/P1.full.pdf. PMID: 26563978
  26. Cohen P, Rogol AD, Deal CL, et al; 2007 ISS Consensus Workshop participants. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008 Nov;93(11):4210-4217. doi: 10.1210/jc.2008-0509. PMID: 18782877
  27. Grimberg A, DiVall SA, Polychronakos C, et al; Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6):361-397. doi: 10.1159/000452150. PMID: 27884013
  28. Richmond EJ, Rogol AD. Diagnosis of growth hormone deficiency in children. UptoDate. http://www.uptodate.com/. Oct 2017.
  29. Snyder PJ. Growth hormone deficiency in adults. UptoDate. http://www.uptodate.com. Oct 2017.
  30. Alexopoulou O, Maiter D. An update on diagnosis and treatment of adult growth hormone deficiency. Louvain Med. 2018;137(3):123-130.
  31. Bozzola M, Meazza C. Growth hormone deficiency: diagnosis and therapy in children. In: Cardenas-Aguayo, ed. Restricted Growth - Clinical Genetic and Molecular Aspects; 2016. 45-72. :45-72.
  32. Deodati A, Cianfarani S. The rationale for growth hormone therapy in children with short stature. J Clin Res Pediatr Endocrinol. 2017 Dec;9(Suppl 2):23-32. doi: 10.4274/jcrpe.2017.S003. PMID: 29280742
  33. Díez JJ, Sangiao-Alvarellos S, Cordido F. Treatment with growth hormone therapy for adults with growth hormone deficiency syndrome: benefits and risks. Int J Mol Sci. 2018 Mar;19(3):893. doi: 10.3390/ijms19030893. PMID: 29562611
  34. Feldt-Rasmussen U, Klose M. Adult growth hormone deficiency clinical management. In: Feingold KR, Anawalt B, Boyce A, et al, eds. Endotext. South Dartmouth (MA): MDText.com, Inc; 2000.
  35. Gabreanu GR. An update on the diagnosis of growth hormone deficiency. Discoveries. 2018 Jan;6(1):e82. doi: 0.15190/d.2018.2.
  36. Garcia JM, Biller BMK, Korbonits M, et al. Macimorelin as a diagnostic test for adult GH deficiency. J Clin Endocrinol Metab. 2018 Aug;103(8):3083-3093. doi: 10.1210/jc.2018-00665. PMID: 29860473
  37. Stanley T. Diagnosis of growth hormone deficiency in childhood. Curr Opin Endocrinol Diabetes Obes. 2012 Feb;19(1):47-52. doi: 10.1097/MED.0b013e32834ec952. . PMID: 22157400
  38. Yuen KC, Biller BMK, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract. 2019 Nov;25(11):1191-1232. doi: 10.4158/GL-2019-0405. PMID: 31760824
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Skipping breakfast before and during early pregnancy ups GDM risk
28 Apr 2020
Women who skip breakfast before and during early pregnancy have a higher risk of developing gestational diabetes mellitus (GDM) than those who have the essential meal daily, suggests a study.
DAPA-CKD heralds a new era for dapagliflozin in kidney disease
Pearl Toh, 23 Sep 2020
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Empagliflozin reduces CV death, HF hospitalization in HFrEF patients
Roshini Claire Anthony, 23 Sep 2020

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.